{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:45:16Z","timestamp":1790646316160,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T00:00:00Z","timestamp":1565568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T00:00:00Z","timestamp":1565568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Auton Res"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s10286-019-00625-9","type":"journal-article","created":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T15:02:40Z","timestamp":1565622160000},"page":"19-24","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review"],"prefix":"10.1007","volume":"29","author":[{"given":"M\u00e1rcia Waddington","family":"Cruz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,12]]},"reference":[{"key":"625_CR1","first-page":"240","volume":"22","author":"F Barroso","year":"2017","unstructured":"Barroso F, Ando Y, Gonzalez-Duarte A, Schmidt H, Mundayat R (2017) Autonomic symptoms in transthyretin amyloidosis: an analysis of symptomatic subjects from the THAOS registry. J Peripher Nerv Syst 22:240","journal-title":"J Peripher Nerv Syst"},{"key":"625_CR2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","volume":"24","author":"FA Barroso","year":"2017","unstructured":"Barroso FA, Judge DP, Ebede B, Li H, Stewart M, Amass L, Sultan MB (2017) Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6\u00a0years. Amyloid 24:194\u2013204","journal-title":"Amyloid"},{"key":"625_CR3","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","volume":"260","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maia LF, da Silva AM, Cruz MW, Plante-Bordeneuve V, Suhr OB, Conceicao I, Schmidt HH, Trigo P, Kelly JW, Labaudiniere R, Chan J, Packman J, Grogan DR (2013) Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 260:2802\u20132814","journal-title":"J Neurol"},{"key":"625_CR4","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plante-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceicao IM, Schmidt HH, Trigo P, Kelly JW, Labaudiniere R, Chan J, Packman J, Wilson A, Grogan DR (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79:785\u2013792","journal-title":"Neurology"},{"key":"625_CR5","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1007\/s00415-016-8064-9","volume":"263","author":"A Cortese","year":"2016","unstructured":"Cortese A, Vita G, Luigetti M, Russo M, Bisogni G, Sabatelli M, Manganelli F, Santoro L, Cavallaro T, Fabrizi GM, Schenone A, Grandis M, Gemelli C, Mauro A, Pradotto LG, Gentile L, Stancanelli C, Lozza A, Perlini S, Piscosquito G, Calabrese D, Mazzeo A, Obici L, Pareyson D (2016) Monitoring effectiveness and safety of tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. J Neurol 263:916\u2013924","journal-title":"J Neurol"},{"key":"625_CR6","volume-title":"Amyloid and amyloidosis","author":"M Coutinho","year":"1980","unstructured":"Coutinho M, Martins da Silva A, Lopes Lima J, Resende Barbosa A (1980) Forty years of experience with type I amyloid neuropathy review of 483 cases. In: Glenner GG, Pinho e Costa P, Falcao De Freitas A (eds) Amyloid and amyloidosis. Excerpta Medica, Amsterdam"},{"key":"625_CR7","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","volume":"99","author":"BG Ericzon","year":"2015","unstructured":"Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR, Furtado E, Barroso E, Daniel J, Samuel D, Adam R, Karam V, Poterucha J, Lewis D, Ferraz-Neto BH, Cruz MW, Munar-Ques M, Fabregat J, Ikeda S, Ando Y, Heaton N, Otto G, Suhr O (2015) Liver transplantation for hereditary transthyretin amyloidosis: after 20\u00a0years still the best therapeutic alternative? Transplantation 99:1847\u20131854","journal-title":"Transplantation"},{"key":"625_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/13506129.2017.1301419","volume":"24","author":"D Keohane","year":"2017","unstructured":"Keohane D, Schwartz J, Gundapaneni B, Stewart M, Amass L (2017) Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid 24:30\u201336","journal-title":"Amyloid"},{"key":"625_CR9","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1212\/WNL.0000000000003362","volume":"87","author":"H Koike","year":"2016","unstructured":"Koike H, Ikeda S, Takahashi M, Kawagashira Y, Iijima M, Misumi Y, Ando Y, Ikeda SI, Katsuno M, Sobue G (2016) Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy. Neurology 87:2220\u20132229","journal-title":"Neurology"},{"key":"625_CR10","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1111\/ene.12225","volume":"20","author":"P Lozeron","year":"2013","unstructured":"Lozeron P, Theaudin M, Mincheva Z, Ducot B, Lacroix C, Adams D, French Network for FAP (2013) Effect on disability and safety of tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol 20:1539\u20131545","journal-title":"Eur J Neurol"},{"key":"625_CR11","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","volume":"6","author":"G Merlini","year":"2013","unstructured":"Merlini G, Plante-Bordeneuve V, Judge DP, Schmidt H, Obici L, Perlini S, Packman J, Tripp T, Grogan DR (2013) Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res 6:1011\u20131020","journal-title":"J Cardiovasc Transl Res"},{"key":"625_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10286-017-0467-x","volume":"29","author":"P Novak","year":"2019","unstructured":"Novak P (2019) Electrochemical skin conductance: a systematic review. Clinical Auton Res 29:17\u201329","journal-title":"Clinical Auton Res"},{"key":"625_CR13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00415-016-8337-3","volume":"264","author":"V Plante-Bordeneuve","year":"2017","unstructured":"Plante-Bordeneuve V, Gorram F, Salhi H, Nordine T, Ayache SS, Le Corvoisier P, Azoulay D, Feray C, Damy T, Lefaucheur JP (2017) Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study. J Neurol 264:268\u2013276","journal-title":"J Neurol"},{"key":"625_CR14","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","volume":"10","author":"V Plante-Bordeneuve","year":"2011","unstructured":"Plante-Bordeneuve V, Said G (2011) Familial amyloid polyneuropathy. Lancet Neurol 10:1086\u20131097","journal-title":"Lancet Neurol"},{"key":"625_CR15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/13506129.2016.1207163","volume":"23","author":"M Waddington Cruz","year":"2016","unstructured":"Waddington Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B (2016) Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid 23:178\u2013183","journal-title":"Amyloid"}],"container-title":["Clinical Autonomic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10286-019-00625-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10286-019-00625-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10286-019-00625-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T23:20:11Z","timestamp":1597101611000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10286-019-00625-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,12]]},"references-count":15,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["625"],"URL":"https:\/\/doi.org\/10.1007\/s10286-019-00625-9","relation":{},"ISSN":["0959-9851","1619-1560"],"issn-type":[{"value":"0959-9851","type":"print"},{"value":"1619-1560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,12]]},"assertion":[{"value":"12 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M\u00e1rcia Waddington Cruz has received honorarium from NHI, Prothena, FoldRx, Ionis, Pfizer, Alnylam, PTC and Genzyme for travel expenses related to presentations at medical meetings and as a consultant member. She has been principal investigator in the TTR trials funded by Ionis, Pfizer and Alnylam.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}